Trump Drug Pricing Deals: 26 Companies, 90% U.S. Market Impact

President Donald Trump announced new drug pricing deals with nine companies, aiming to reduce outpatient drug costs across state Medicaid programs. This brings the total number of drug pricing agreements to 26, covering 90% of the U.S. pharmaceutical market. The agreements are part of a broader strategy to align domestic drug prices with those in foreign countries. Notably, U.S. prescription drug prices average nearly three times higher than abroad, affecting the bottom lines of drug manufacturers. These developments may influence healthcare affordability, crucial as the midterm elections approach.